Roth Capital Has Strong Forecast for InfuSystem Q4 Earnings

InfuSystem Holdings, Inc. (NYSE:INFU) – Research analysts at Roth Capital boosted their Q4 2025 earnings per share estimates for InfuSystem in a research note issued to investors on Tuesday, November 4th. Roth Capital analyst K. Bauser now expects that the company will post earnings per share of $0.06 for the quarter, up from their previous estimate of $0.05. Roth Capital has a “Buy” rating and a $14.00 price objective on the stock. The consensus estimate for InfuSystem’s current full-year earnings is $0.15 per share. Roth Capital also issued estimates for InfuSystem’s Q2 2026 earnings at $0.08 EPS.

Several other research analysts also recently weighed in on the company. Zacks Research downgraded InfuSystem from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Lake Street Capital began coverage on shares of InfuSystem in a research note on Monday, September 22nd. They set a “buy” rating and a $15.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, InfuSystem has an average rating of “Buy” and an average target price of $14.50.

InfuSystem Price Performance

INFU stock traded down $0.23 during trading on Friday, hitting $10.06. The stock had a trading volume of 34,094 shares, compared to its average volume of 187,158. The stock has a market cap of $205.49 million, a price-to-earnings ratio of 166.78 and a beta of 1.80. InfuSystem has a 1-year low of $4.61 and a 1-year high of $11.04. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. The company’s 50 day moving average price is $10.07 and its two-hundred day moving average price is $7.67.

Insider Buying and Selling

In other InfuSystem news, Director Scott Shuda sold 5,752 shares of the company’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $9.67, for a total transaction of $55,621.84. Following the completion of the transaction, the director owned 94,000 shares of the company’s stock, valued at $908,980. This represents a 5.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 11.40% of the company’s stock.

Institutional Trading of InfuSystem

Institutional investors have recently made changes to their positions in the business. CWM LLC boosted its stake in shares of InfuSystem by 1,160.1% during the 2nd quarter. CWM LLC now owns 4,826 shares of the company’s stock worth $30,000 after buying an additional 4,443 shares during the last quarter. Raymond James Financial Inc. bought a new position in InfuSystem in the second quarter valued at approximately $33,000. Jump Financial LLC acquired a new position in shares of InfuSystem during the 1st quarter worth approximately $58,000. Williams & Novak LLC bought a new stake in shares of InfuSystem during the 2nd quarter worth approximately $77,000. Finally, Virtu Financial LLC acquired a new stake in shares of InfuSystem in the 1st quarter valued at approximately $86,000. Institutional investors own 71.13% of the company’s stock.

InfuSystem Company Profile

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.